No association between gender-affirming hormone therapy and diabetes risk
02 December 2021
2 minutes to read
Source / Disclosures
The authors do not report any relevant financial disclosures.
According to an analysis of electronic health record data, transgender people who were prescribed gender-affirming hormone therapy were no more likely to develop type 2 diabetes than cisgender adults.
“The results of our study are reassuring that gender-affirming therapy does not increase the risk of type 2 diabetes, but our analysis was not designed to assess more subtle subclinical changes.” Noreen Islam, MD, MPH, a member of the pediatric endocrinology division of Emory University medical school, said in a press release. “For this reason, health care providers should continue to monitor the metabolic status of people receiving gender-affirming therapy.”
Islam and colleagues analyzed FSD data from 2,869 transgender or transfeminine women matched by age, race, calendar year, and location with 28,300 cisgender women and 28,258 cisgender men, as well as 2,133 matched transgender or transmasculine men with 20,997 cisgender women and 20,964 cisgender men. All patients were enrolled in one of three Kaiser Permanente health systems in Northern California, Southern California, and Georgia, and were followed from 2006 to 2014, with extended follow-up through 2016. The researchers used proportional hazard and logistic regression Cox models, controlled for BMI, to assess data on the incidence and prevalence of type 2 diabetes.
âMale and female cisgender reference groups were used because serum hormone levels in transgender people can range from normal male physiological levels to normal female physiological levels, depending on the route of administration and dosage of the drug. ‘hormone therapy, as well as individual characteristics, “the researchers wrote.
Researchers found that prevalent and incident type 2 diabetes was more common in transgender women than in cisgender women, with an OR of 1.3 (95% CI, 1.1-1.5) and an RR 1.4 (95% CI, 1.1-1.8), respectively. There was no difference between groups in the prevalence or incidence of diabetes in the remaining comparison groups, both overall and among transgender and gender diverse people with evidence of use of HT by affirming the genre.
“While more research is needed, there is little evidence that the onset of type 2 diabetes in transgender women or transgender men is attributable to gender-affirming hormone therapy, at least in the short term,” said Islam in the press release.
The researchers noted that the analysis lacked data on other risk factors for type 2 diabetes, including family history, socioeconomic status, adverse childhood experiences and information on minority stress. gender, which has been associated with a wide range of adverse clinical outcomes.
“Given the apparent lack of association between receipt of gender-affirming HT and the incidence of type 2 diabetes in our study, further research should focus on the hypothetical effect of stress on gender-affirming minorities. gender and its interaction with metabolic lifestyle risk factors in transgender people, âthe researchers wrote.
For more information:
Noreen Islam, MD, MPH, can be contacted at [email protected]